BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in the obesity drug market is ...

Novo can now meet the demand for Ozempic and Wegovy ... as allowed by law to meet patient needs,” Dudum said in a post on X. ...

Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

An X post from Elon Musk on Wednesday highlighted Tesla (TSLA) CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler’s Chief Market ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...

German software developer SAP SE unseated Danish weight-loss drug maker Novo Nordisk A/S as Europe’s most-valuable public company. Shares of SAP, which have surged as the Walldorf, Germany-based ...

Then €69 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.

Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial ...

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...